A5090500222- Parkinson's Disease Mechanisms and Treatments
- Cholinesterase and Neurodegenerative Diseases
- Botulinum Toxin and Related Neurological Disorders
- Complementary and Alternative Medicine Studies
- Corporate Social Responsibility Reporting
- Alzheimer's disease research and treatments
- Attention Deficit Hyperactivity Disorder
- Economic Growth and Development
- Dementia and Cognitive Impairment Research
- Psychedelics and Drug Studies
- Health Systems, Economic Evaluations, Quality of Life
- Schizophrenia research and treatment
- Environmental Sustainability in Business
Management Development Institute
2024
Acadia Pharmaceuticals (United States)
2022-2024
Pimavanserin, a 5-HT2A receptor inverse agonist/antagonist, is the only medication approved by FDA for treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Further expanding knowledge safety profile pimavanserin in PDP neurodegenerative diseases (NDD) such as Alzheimer's great interest informing its use patients (with or without dementia), given this population highly sensitive to adverse effects following antipsychotic use.
Pimavanserin is FDA-approved to treat Parkinson's disease (PD) psychosis. We analyzed the effect of pimavanserin on psychosis in PD dementia (PDD) subgroup from phase 3 HARMONY trial.
Objective: This study examines the influence of different ownership structures on corporate social responsibility spending in a mandatory CSR regime. Method: We use data under statutory mandate reported by top 500 publicly listed Indian firms first four years after law implementation 2014 Bombay Stock Exchange and Ministry Corporate Affairs website. Using institutional agency theory arguments, we hypothesize that structure influences spending. multiple logistics regression for our...
Alzheimer’s disease psychosis (ADP) produces a significant burden for patients and their care partners, but at present there are no approved treatments ADP. The lack of may be due to the challenges conducting clinical trials this disease. This perspective article discusses distinct proposed solutions ADP involving seven key areas: (1) methods reduce variable sometimes high rates placebo response that occur neuropsychiatric symptoms; (2) use combined or updated criteria provide precise,...
Purpose : Extant literature on corporate social responsibility (CSR) provided insights into its antecedents and outcomes; however, more scholarly attention must be given to CSR implementation. India was the first country in world adopt law 2014; firms coming under preview of were expected choose a implementation mode for every project further report it as part yearly reporting. Therefore, need understand various modes increased. This paper addressed this gap by defining then comparing these...
Abstract Background Patients with neurodegenerative diseases including Parkinson’s disease often experience neuropsychiatric symptoms, hallucinations and delusions, apathy, agitation. 1,2 These symptoms can greatly impair daily function lead to reduced quality of life significant caregiver burden. patients are generally elderly frail. Treatment options limited, representing a substantial unmet need. Pimavanserin, 5‐HT 2A receptor inverse agonist/antagonist, is FDA‐approved treat delusions...
Abstract Alzheimer’s disease psychosis (ADP) is a common and serious condition with substantial unmet need for safe effective treatments. Pimavanserin approved in the US to treat Parkinson’s hallucinations delusions. This post-hoc analysis of randomized, double-blind, placebo-controlled, phase 2 trial nursing-home-residents ADP evaluated efficacy pimavanserin by improvements (least squares mean change) Neuropsychiatric Inventory–Nursing Home Version Psychosis Score (NPI-NH PS). The clinical...
Abstract Background Pimavanserin was investigated for the treatment of dementia‐related psychosis (DRP) in HARMONY (NCT03325556), a phase 3 randomized discontinuation study. As study met primary endpoint (one‐sided P = 0.0023), we evaluated consistency efficacy reducing risk relapse largest dementia patient subgroup (ie, Alzheimer’s [ADP] patients) treated with pimavanserin 34mg. Method Enrolled DRP patients (N 392) entered 12‐week open‐label (OL) period and received 34mg daily. During weeks...